Enterprise Value

0.00

Cash

77.4M

Avg Qtr Burn

N/A

Short % of Float

2.36%

Insider Ownership

0.19%

Institutional Own.

34.47%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
FOTIVDA (Tivozanib) (VEGFR 123 TKI) Details
Kidney cancer, Carcinoma , Genetic disorder, Rare genetic disease, Renal cell carcinoma

Approved

Quarterly sales